Drug intelligence / Profile preview

VX18

Development stage: Preclinical
Lead developer: Vaccinex
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

VX18 is a monoclonal antibody currently in the preclinical drug discovery phase, developed by Vaccinex under the Pepinemab Development Venture. It is being investigated for potential therapeutic applications in the fields of neurology and inflammatory diseases. As a discovery-stage asset, its specific molecular target and mechanism of action have not yet been publicly disclosed. It represents an expansion of the developer's pipeline beyond its lead candidate, pepinemab, focusing on addressing unmet needs in neurodegenerative and chronic inflammatory conditions.

Targets

SEMA4D (Semaphorin 4D)

Beyond the preview

Go deeper on VX18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VX18.

Explore the full profile